FDA approves large-scale clinical trials of ecstasy to treat patients with PTSD

Currently, MDMA has a strictly negative view in the public eye. It is seen simply as a party drug that is mainly taken at raves. However, a drug trial green-lighted by the FDA has been showing promise in the use of the drug to help treat PTSD and autism. Ecstasy has been banned since 1986, but recent research claims that giving it to autistic or PTSD patients could create a strong psychological experience that helps them feel more empathetic and connect better emotionally with a therapist. The phase three trial will include 230 or more patients.

Key Takeaways:

  • Scientists in the United States will treat 230 PTSD patients with ecstasy.
  • Ecstasy is currently restricted as a Schedule 1 drug, the same as heroin and LSD.
  • If the trial is successful, ecstasy could be publicly available for medical use in 2021.

“If the trial is successful, ecstasy – also known as MDMA, Molly, and (officially) methylenedioxymethamphetamine – could be publicly available for medical use in 2021.”